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Increases in glucose concentration control the tran-
scription of the preproinsulin (PPI) gene and several
other genes in the pancreatic islet b-cell. Although re-
cent data have demonstrated that secreted insulin may
regulate the PPI gene (Leibiger, I. B., Leibiger, B.,
Moede, T., and Berggren, P. O. (1998) Mol. Cell 1, 933–
938), the role of insulin in the control of other b-cell
genes is unexplored. To study the importance of insulin
secretion in the regulation of the PPI and liver-type
pyruvate kinase (L-PK) genes by glucose, we have used
intranuclear microinjection of promoter-luciferase con-
structs into MIN6 b-cells and photon-counting imaging.
The activity of each promoter was increased either by 30
(versus 3) mM glucose or by 1–20 nM insulin. These effects
of insulin were not due to enhanced glucose metabolism
since culture with the hormone had no impact on the
stimulation of increases in intracellular ATP concentra-
tion caused by 30 mM glucose. Furthermore, the islet-
specific glucokinase promoter and cellular glucokinase
immunoreactivity were unaffected by 30 mM glucose or
20 nM insulin. Inhibition of insulin secretion with the
Ca21 channel blocker verapamil, the ATP-sensitive K1
channel opener diazoxide, or the a2-adrenergic agonist
clonidine blocked the effects of glucose on L-PK gene
transcription. Similarly, 30 mM glucose failed to induce
the promoter after inhibition of phosphatidylinositol 3*-
kinase activity with LY294002 and the expression of
dominant negative-acting phosphatidylinositol 3*-ki-
nase (Dp85) or the phosphoinositide 3*-phosphatase
PTEN (phosphatase and tensin homologue). LY294002
also diminished the activation of the L-PK gene caused
by inhibition of 5*-AMP-activated protein kinase with
anti-5*-AMP-activated protein kinase a2 antibodies.
Conversely, stimulation of insulin secretion with 13 mM
KCl or 10 mM tolbutamide strongly activated the PPI and
L-PK promoters. These data indicate that, in MIN6
b-cells, stimulation of insulin secretion is important for
the activation by glucose of L-PK as well as the PPI
promoter, but does not cause increases in glucokinase
gene expression or glucose metabolism.
Elevated glucose concentrations stimulate the transcription
of the preproinsulin (PPI)1 gene (1, 2) and several other genes
in islet b-cells, including the liver-type pyruvate kinase (L-PK)
gene (3), acetyl-CoA carboxylase I (4), GLUT2 (5), and a raft of
other genes involved in insulin synthesis and release (6). How-
ever, the molecular mechanisms involved in the regulation of
transcription by glucose are only partly understood (7, 8). Re-
cent observations have suggested that the release of insulin
may play an important part in the regulation of the preproin-
sulin gene by glucose, at least under certain conditions (9, 10).
Consistent with this, increases in intracellular free Ca21 con-
centration ([Ca21]i), which are important in the activation of
insulin release, have been reported to be essential for regula-
tion of PPI gene expression by glucose in some systems (11, 12).
On the other hand, several studies have indicated that glucose
can also regulate the PPI gene independently of insulin secre-
tion (13–15). Furthermore, PPI gene expression appears to be
largely unaltered after targeted disruption of the insulin recep-
tor gene in the islet b-cell, at least in younger animals (16).
By contrast, the role of insulin secretion in the regulation of
other glucose-sensitive islet b-cell genes is largely uninvesti-
gated (8, 17). Elevations of glucose concentration enhance the
expression of the L-PK gene in hepatocytes through activated
transcription (18). This effect of glucose is dependent upon a
cis-acting upstream region of the gene from nucleotides 2183
to 110 with respect to the cap site (19), and a glucose response
element has been mapped to a palindromic repeat of two E-
boxes (CACGGG) located in the region at base pairs 2170 to
2150 with respect to the transcriptional start site (20). A
similar region is also present in other glucose-responsive genes
(8), including those encoding Spot14 (21), acetyl-CoA carboxyl-
ase I (22, 23), and fatty-acid synthase (24).
Phosphorylation of glucose appears to be essential for the
transcriptional effects of the sugar on L-PK gene transcription
in liver (7). Thus, glucose 6-phosphate and the pentose phos-
phate intermediate xylulose 5-phosphate (25) may be key sig-
naling intermediates. The identity of the transcription factors
mediating the transcriptional response is still debated, with
evidence both for (26, 27) and against (28, 29) a role for the
ubiquitous upstream stimulatory factor (USF1 and USF2). Re-
cent data have also implicated sterol response element-binding
protein-1c (SREBP-1c) (30) and other less well defined factors
(31).
L-PK gene transcription is also strongly stimulated by insu-
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lin in cultured liver cells. Under most experimental conditions,
this effect requires elevated glucose concentrations and has
been considered to be due mainly to up-regulation of the glu-
cokinase (GK) gene (32) and thus increased intracellular con-
centrations of Glu-6-P or xylulose 5-phosphate (33, 34). How-
ever, insulin also activates the L-PK promoter after culture of
hepatocytes from starved rats after constitutive expression of
GK (35), indicating that an additional, glucose-independent
mechanism of action of the hormone must exist.
Since high glucose concentrations stimulate islet GK gene
expression relatively weakly (36, 37), if at all (3, 32), the induc-
tive effect of glucose on L-PK gene transcription in islets and
b-cell-derived INS-1 (3) and MIN6 (26, 38) cells has previously
been attributed solely to an increase in the intracellular con-
centration of a glucose metabolite (e.g. Glu-6-P or xylulose
5-phosphate; see above). However, glucose also stimulates the
release of stored insulin from the b-cell, so the potential exists
for a para- or autocrine effect of the hormone on gene expres-
sion. We have therefore investigated the effects of added insu-
lin on the PPI, L-PK, and GK gene promoters in the highly
glucose-responsive model MIN6 b-cell line (39). This system
has enabled us to determine the relative importance of acti-
vated insulin secretion, glucose metabolism, and changes in
[Ca21]i in the transcriptional regulation of the L-PK gene by
glucose. Our results suggest that, under appropriate condi-
tions, secretion of insulin and the activation of a signaling
pathway dependent upon phosphatidylinositol 39-kinase
(PI3K) largely explain the transcriptional effects of glucose on
PPI and L-PK gene expression in this b-cell model.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium was from Sigma
(Dorset, United Kingdom) or Life Technologies, Inc. (Paisley, UK).
Beetle luciferin was from Promega, and coelenterazine was from Mo-
lecular Probes, Inc. Polyclonal anti-glucokinase antibody (sc-7908) was
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). LY294002 was
from Calbiochem-Novabiochem (Nottingham, UK). Porcine insulin was
from Sigma. Other reagents were from Sigma or BDH.
Plasmids—pLPK-LucFF and p(2150)LPK-LucFF contained nucleo-
tides 2183 to 110 and 2148 to 110, respectively, of the rat L-PK
promoter fused immediately upstream of humanized firefly luciferase
cDNA (Promega plasmid pGL3-BasicTM). Plasmid pINS-LucFF con-
tained nucleotides 2260 to 260 of the human insulin promoter fused
upstream of a minimal herpes simplex thymidine kinase promoter and
luciferase cDNA (40). The expression plasmid for Renilla luciferase
(pRL-CMV) was purchased from Promega. pSRaDp85 (provided by Prof.
J. Tavare´) was used to express, under SV40 promoter control, a domi-
nant negative-acting mutant of the p85 subunit of PI3K that lacks the
binding site for the catalytic p110 subunit of PI3K (41). Plasmid
pCMV5-PTEN was supplied by Prof. J. E. Dixon (University of Michi-
gan). Plasmid bGK4-Luc, containing region 24000 to 11 of the rat
b-cell glucokinase promoter (3), was provided by Dr. P. Iynedjian (Uni-
versity of Geneva, Geneva, Switzerland).
Antibodies—Affinity-purified sheep antibodies raised against rat 59-
AMP-activated protein kinase (AMPK) a2 (42) were provided by Prof.
D. G. Hardie (University of Dundee, Dundee, Scotland) and extensively
dialyzed against microinjection buffer (2 mM Tris-HCl (pH 8.0) and 0.2
mM Na1-EDTA) before use.
Cell Culture—MIN6 b-cells (39) were used between passages 19 and
25 and grown in Dulbecco’s modified Eagle’s medium containing 15%
(v/v) heat-inactivated fetal calf serum, 25 mM glucose, 5.4 mM KCl, 2 mM
glutamine, 100 mM b-mercaptoethanol, 100 IU/ml penicillin, and 100
mg/ml streptomycin in a humidified atmosphere at 37 °C with 5% CO2
unless specified otherwise. Cells were transferred to medium contain-
ing 3 mM glucose 16 h prior to experiments. Secreted insulin was
measured by radioimmunoassay (Linco Research Inc., St. Charles, MO)
(43).
Infection with Adenoviruses—Cells were exposed to adenoviruses
(30–100 viral particles/cell) for 2 h prior to culture for a further 24 h in
the absence of added virus (43).
Microinjection and Luciferase Imaging—Intranuclear microinjection
of plasmids and antibodies was performed using an Eppendorf 5121/
5246 micromanipulator (26, 44) at plasmid concentrations of 0.1 (LucFF-
based vectors) and 0.05 (pCMV-RL) mg/ml and a total antibody concen-
tration of 1–1.5 mg/ml (Bradford assay (45)) in 2 mM Tris-HCl, pH 8.0,
0.2 mM EDTA (38). Plasmid pSRaDp85 or the corresponding empty
vector (p85SRa) was injected at 0.1 mg/ml. Individual experiments
involved injection of 100–200 separate cells/condition, with an effi-
ciency of 5–20% productive injection as assessed by expression of Re-
nilla reniformis luciferase activity. Cells were imaged 6 h after micro-
injection and cultured under the conditions described above. Photon-
counting imaging of firefly and R. reniformis luciferase activities was
performed in single living cells using an Olympus IX-70 inverted mi-
croscope (310 air objective, 0.4 NA) and an intensified charge-coupled
device camera (Photek, East Sussex, UK) as described in detail
previously (26, 46).
Measurement of [Ca21]i and Insulin Secretion—Changes in [Ca
21]i
were measured at 37 °C with entrapped fura-2 (43, 47) using a Leica
DM-IRBI inverted microscope (340 objective) and a Hamamatsu
C4742-995 charge-coupled device camera driven by OpenLabTM soft-
ware (Improvision, Coventry, UK) (43, 48). Cells were loaded for 40 min
in modified Krebs-Ringer bicarbonate (KRB) buffer (125 mM NaCl, 3.5
mM KCl, 1.5 mM CaCl2, 0.5 mM MgSO4, 0.5 mM KH2PO4, 2.5 mM
NaHCO3, and 10 mM Na
1-Hepes (pH 7.4) initially containing 3 mM
glucose and equilibrated with 95:5 O2/CO2) supplemented with 5 mM
fura-2/AM (Sigma) and 0.1% Pluronic F-127 (BASF, Mount Olive, NJ).
Insulin released into the culture medium was assayed by radioimmu-
noassay (Linco Research Inc.) (43).
Intracellular ATP Concentration Imaging with Recombinant Ex-
pressed Luciferase—Cytosolic luciferase (49) was expressed using an
adenoviral vector (50) under constitutive (CMV) promoter control (Ad-
CMVcLuc)2 and monitored by real-time photon-counting imaging dur-
ing perifusion in KRB buffer (37 °C) (43, 49).
Statistical Analysis—Data are given as means 6 S.E. of three to five
individual experiments. Comparisons between means were performed
using one-tailed Student’s t test for paired data with Microsoft ExcelTM.
RESULTS
Regulation of the PPI Promoter by Glucose and Exogenous
Insulin in Single MIN6 b-Cells—The activity of the human PPI
promoter (base pairs 2260 to 260 with respect to the transcrip-
tional start site) (40) was measured by single cell luminescence
assay (46) after microinjection of a firefly luciferase reporter
construct. This promoter region contains the homeodomain-
binding elements A1, A2, and A3, as well as the E-boxes E1 and
E2 (51). PPI promoter activity was normalized to that of the
CMV immediate-early gene promoter, linked to the expression
of R. reniformis luciferase (26, 46, 52). In a previous report (14),
we described conditions under which the PPI promoter was
regulated in single MIN6 b-cells by glucose, independently of
secreted insulin. In the present study, we observed that, by
culturing MIN6 cells at (a) a lower passage number (passages
19–25) and (b) a lower density (thus decreasing the contribu-
tion of secreted insulin at low glucose concentrations), the PPI
promoter was up-regulated more strongly (5–10-fold versus
1.5–2-fold in our previous report (14)) by 30 mM glucose and to
a similar extent by 20 nM insulin (Fig. 1). The effect of 30 mM
glucose was strongly inhibited by the L-type Ca21 channel
inhibitor verapamil and the type I PI3K inhibitor LY294002
(38). The effects of 30 mM glucose were also mimicked by low
concentrations of KCl (13 mM) (Fig. 1), as previously reported
for islet b-cells and HIT-T15 cells (9). However, higher KCl
(.30 mM) and insulin (100 nM) concentrations were ineffective
(data not shown), as described in previous MIN6 cultures (49).
Regulation of the L-PK Promoter by Glucose and Exogenous
Insulin—In MIN6 cells co-microinjected with a minimal L-PK
promoter (base pairs 2183 to 110)-firefly luciferase reporter
construct (26) and maintained for 6 h at 3 mM glucose, the ratio
of firefly to Renilla luciferase activity was in the range 0.02–
0.15, with higher values associated with later cell passage
numbers. In common with previous studies (26, 52), 30 mM
glucose stimulated the L-PK promoter by 3.6 6 0.07-fold (11
2 G. A. Rutter and E. K. Ainscow, submitted for publication.
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separate experiments, n 5 108 and 126 cells incubated at 3 and
30 mM glucose, respectively; p , 0.001 for the effect of 30 mM
glucose) (Fig. 2, A, panel b; and B). This effect was mimicked by
the addition of exogenous insulin (20 nM). Thus, in 11 experi-
ments on separate cultures, 20 nM insulin increased the activ-
ity of the L-PK promoter in cells maintained at 3 mM glucose by
3.3 6 0.002-fold (n 5 108 control and 67 insulin-stimulated
cells; p , 0.001) (Fig. 2, A, panel c; and B). By contrast, added
insulin was entirely without effect at stimulatory glucose con-
centrations (30 mM) (Fig. 2, A, panels b and d; and B). At 3 mM
glucose, the effect of insulin was clearly apparent at low phys-
iological concentrations of the hormone, with 1 nM insulin pro-
viding .50% maximal stimulation of promoter activity (Fig.
2C). By contrast, 100 nM insulin failed to stimulate L-PK pro-
moter activity significantly (Fig. 2C).
To determine whether secretion of insulin may be responsi-
ble for the increase in L-PK promoter activity at high glucose
concentration, we measured the concentrations of insulin pres-
ent in the incubation medium at the end of the culture period.
After 6 h of incubation at 3 and 30 mM glucose, the medium
insulin concentrations were 7.08 6 2.25 and 13.3 6 4.25 nM,
respectively (n 5 three separate cultures). Thus, elevated glu-
cose stimulated insulin secretion in the cell cultures as ex-
pected and over a range to which the L-PK promoter was
sensitive (Fig. 2C). We next tested the effect of blocking the
exocytosis of insulin in response to glucose with verapamil. In
the presence of this inhibitor, 30 mM glucose had no effect on
L-PK promoter activity (Fig. 2, A, panels e and f; and B).
However, in the presence verapamil, the addition of 20 nM
insulin still caused a marked activation of L-PK promoter
activity at 3 or 30 mM glucose (Fig. 2, A, panels e–h; and B),
demonstrating that the effects of verapamil are unlikely to be
due to any nonspecific toxic effects of the drug. Similarly,
diazoxide, which opens the ATP-sensitive K1 channel (53) and
thus prevents cell depolarization and [Ca21]i increases (Fig.
3c), also eliminated induction of the L-PK promoter with 30 mM
glucose (Fig. 3a). To determine whether the effects of diazoxide
or verapamil may be due to an inhibition of Ca21-dependent
glucose metabolism (49, 54), we used adenovirally expressed
firefly luciferase,2 under the control of the strong cytomegalo-
virus immediate-early gene promoter, to monitor the free cyto-
plasmic ATP concentration in real time (49). Perifusion of cell
populations with 30 mM glucose led to a clear and rapid in-
crease in ATP-dependent luciferase bioluminescence (;15%
above basal levels), which was unaffected by the presence of
200 mM diazoxide (Fig. 3d). Finally, inhibition of insulin secre-
tion with the a2-adrenergic agonist clonidine (1 mM), which has
no effect on glucose-induced [Ca21]i or [ATP] increases (data
not shown),3 also strongly inhibited the effect of glucose on the
L-PK promoter (Fig. 3b). Clonidine had no impact on the ability
of insulin (20 nM) to stimulate the L-PK promoter (Fig. 3b).
To test whether the activation of insulin secretion may be
sufficient, in the absence of a nutrient stimulus, to activate the
L-PK promoter, we next examined the effects of low concentra-
tions of non-nutrient secretagogues. Increasing the concentra-
tion of KCl in the culture medium from 5.4 to 13 mM or adding
10 mM tolbutamide stimulated L-PK promoter activity strongly
(Fig. 4, a and c). Measured in perifused cells, each agent caused
a clear, but relatively small increase in [Ca21]i (Fig. 4, b and d).
Importantly, the increase in [Ca21]i elicited by the lower con-
centrations of KCl and tolbutamide resembled closely that
evoked by 30 mM glucose (an increase in fura-2 emission ratio
of ;0.15 arbitrary ratio units). The addition to the medium of
higher concentrations of either agent (30 mM KCl or 200 mM
tolbutamide) stimulated the L-PK promoter much more weakly
(Fig. 4, a and c) while causing much larger increases in [Ca21]i
(Fig. 4, b and d) and insulin secretion (data not shown). How-
ever, a clear decrease in cell viability and cell morphology was
apparent after 6 h of incubation with these agents (data not
shown).
Effect of PI3K Inhibition on the Activation by Glucose of the
L-PK Promoter—We next examined the dependence of the ef-
fects of glucose on activation of PI3K. The PI3K inhibitor
LY294002 completely abolished the effect of 30 mM glucose
(Fig. 5a). Indeed, under these conditions, L-PK promoter activ-
ity was significantly inhibited at 30 mM glucose compared with
3 mM glucose. To determine whether the inhibitory effect of
high glucose may be due to an (undefined) response element
lying 39 to the L-PK glucose response element, we also exam-
ined the effects of glucose on the activity of a truncated L-PK
promoter bearing only nucleotides 2148 to 1 10. This promoter
FIG. 1. Regulation of PPI promoter activity by glucose and
insulin. MIN6 cells were microinjected with plasmids pPPI-LucFF (0.1
mg/ml) and pCMV-RL (0.05 mg/ml) as described under “Experimental
Procedures” before culture for 6 h at the indicated glucose concentra-
tions with the following additions: none (upper panel, panels a and b),
50 mM LY294002 (panels c and d), 20 nM insulin (panels e and f), 13 mM
KCl (final concentration; panel g), and 100 mM verapamil (panel h).
Normalized PPI promoter activity (obtained from the ratio of firefly to
Renilla luciferase activities; pseudo-color) was determined after photon-
counting imaging in the presence of luciferin and coelenterazine n.
Shown are typical regions (;0.06 mm2) from a total injected area of
;0.25 mm2. Scale bar 5 50 mm. The pseudo-color bar represents the
ratio of firefly luciferase (reporting PPI promoter activity) to Renilla
luciferase activity (CMV promoter). Combined data (means 6 S.E.)
from three separate experiments are shown in the lower panel and
report observations on the total number of individual cells given on the
bars. ***, p , 0.001 for the effect of glucose, insulin, or KCl.
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was also significantly inhibited by 30 versus 3 mM glucose (Fig.
5a). Confirming that the effects of LY294002 were likely to be
specific for PI3K, overexpression of a dominant-negative form
of the PI3K adaptor subunit (Dp85) lacking the domain respon-
sible for binding the catalytic subunit of PI3K (p110) (38, 41)
led to activation of the L-PK promoter in cells maintained at 3
FIG. 2. Effect of glucose and insulin
on the L-PK gene promoter in single
MIN6 b-cells. A, cells were microinjected
with plasmids pLPK-LucFF (0.1 mg/ml)
and pCMV-RL (0.05 mg/ml) as described
under “Experimental Procedures” before
culture for 6 h at the indicated glucose
concentrations with the following addi-
tions: none (panels a and b), 20 nM insulin
(panels c and d), 100 mM verapamil (pan-
els e and f), and 100 mm verapamil plus 20
nM insulin (panels g and h). Photon pro-
duction by firefly (reporting L-PK pro-
moter activity) and Renilla (reporting
CMV promoter activity) luciferases was
quantitated as described under “Experi-
mental Procedures,” and the ratio of the
two was calculated to provide a normal-
ized assay of L-PK promoter function
(pseudo-color). Scale bar 5 50 mm. B, data
were from two to five separate experi-
ments as shown in A, involving the num-
ber of cells given. Verap, verapamil. C,
shown is the dose response for added in-
sulin (3 mM glucose). Data were from
10–70 cells for each insulin concentra-
tion. *** and *, p , 0.001 and p , 0.05 for
the effect of 30 mM glucose (30 G), respec-
tively; 111 and 11, p , 0.001 and p ,
0.01 for the effect of insulin, respectively.
FIG. 3. Effect of inhibiting insulin
secretion on L-PK promoter activity.
a and b, microinjection and imaging were
performed as described in the legend to
Fig. 2, with additions of diazoxide (diaz;
200 mM) and clonidine (1 mM) as indicated.
The number of injected cells (from three
separate cultures) is given on the bars. **
and *, p , 0.01 and p , 0.05 for the effect
of glucose, respectively; 11 and 111,
p , 0.01 and p 0.001 for the effect of 20 nM
insulin (Ins), respectively. c, changes in
[Ca21]i in response to an increase in peri-
fusate glucose concentration from 3 to 30
mM glucose (30 G) were measured in fura-
2-loaded cells. Data were from experi-
ments on four separate cultures and are
the means 6 S.E. of values from 49 con-
trol cells or 50 cells preincubated and
perifused in the presence of diazoxide. d,
cytosolic [ATP] was measured in AdCM-
VcLuc-transduced cells as described un-
der “Experimental Procedures.” Shown
are typical traces from three separate ex-
periments. The presence of diazoxide
(added 5 min prior to 30 mM glucose) in c
and d is indicated by the open symbols.
The time bars represent 60 s.
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mM glucose, but a powerful inhibition of promoter activity in
cells maintained at 30 mM glucose (Fig. 5b).
To determine whether the inositol phospholipid or protein
kinase activities of PI3K (55) mediated the effects of glucose
and insulin on L-PK promoter activity, we examined the effects
of overexpressing the inositol-39-phosphate phosphatase PTEN
(phosphatase and tensin homologue) (56). PTEN expression
completely ablated the activation of the L-PK promoter by
glucose (Fig. 5c).
Effects of Glucose and Insulin on Glucokinase Promoter Ac-
tivity—Adenovirally mediated overexpression of liver glucoki-
nase (57, 58) strongly increased L-PK promoter activity both at
3 mM glucose (from a firefly/R. reniformis luminescence ratio of
0.008 (n 5 12 null virus-infected cells) to 0.196 (n 5 16 GK
virus-infected cells)) and at 30 mM glucose (from 0.129 (n 5 39
null cells) to 0.241 (n 5 9 infected cells)). However, at 3 mM
glucose, insulin (20 nM) still elicited a further induction of L-PK
promoter activity after the overexpression of GK (firefly/R.
reniformis luminescence ratio of 0.73 6 0.08, n 5 six insulin-
treated cells). Furthermore, neither 30 mM glucose nor exoge-
nous insulin (20 nM) affected the activity of a reporter construct
encoding 4 kilobase pairs of the islet-specific glucokinase pro-
moter (Fig. 6a) (59). Finally, immunocytochemical analysis re-
vealed no detectable change in the level of glucokinase protein
after 6 h culture at 3 or 30 mM glucose or at 3 mM glucose plus
insulin (data not shown).
Effect of Glucose and Insulin on Intracellular Free ATP Con-
centration—To examine further whether the effects of insulin
or elevated glucose may be due to an enhancement of glucose
metabolism independent of glucokinase gene expression, we
used adenovirally expressed firefly luciferase2 as described
above (49). Demonstrating that this assay reported increases in
glycolytic flux, overexpression of glucokinase with the adeno-
viral vector dramatically altered the responses of intracellular
[ATP] to changes in glucose concentration (Fig. 6b). In control
(null virus-infected) cells, increases in apparent cellular free
[ATP] were not evident until the glucose concentration was
raised to 30 mM (Fig. 6b, open circles) and were substantially
blocked by the GK inhibitor mannoheptulose (data not shown).
By contrast, in GK-overexpressing cells, intracellular free
[ATP] was increased considerably by 3 mM glucose, but lowered
when glucose was further raised to 30 mM (Fig. 6b, closed
circles). This drop presumably reflects ATP consumption by the
glucokinase reaction itself under conditions in which distal
steps in glycolysis or glucose oxidation exert a significant con-
trol strength (58). The increase in luminescence of 15–20% seen
in control cells in response to 30 mM glucose (Figs. 3, d; and 6,
b–d) was unaffected by culture in the presence of insulin for 6 h
(Fig. 6c) or after acute (5 min) exposure to the hormone (Fig.
6d). These experiments also reveal that the contribution of
changes in [ATP] to the changes in the apparent promoter
activity reported with firefly luciferase constructs are unlikely
to exceed 20% (and have therefore been ignored).
Role of PI3K in the Effects of AMPK-a2—We have previously
demonstrated that inhibition of the a2 form of AMPK activates
the L-PK promoter, mimicking the effect of glucose (52). To
determine whether AMPK lies upstream or downstream of
PI3K, we examined the effect of PI3K inhibition when AMPK
activity had been inhibited by microinjection of anti-AMPK-a2
antibodies (52) (Fig. 7). The stimulatory effect of inhibiting
FIG. 4. Effect of glucose-independ-
ent activation of insulin secretion on
L-PK promoter activity. Microinjec-
tion, luciferase imaging, and measure-
ments of [Ca21]i were performed as de-
scribed in the legend to Fig. 2. Cells were
incubated in culture medium at the indi-
cated glucose and KCl concentrations (a
and c) or perifused in KRB buffer at 3 mM
glucose (b and d). In all cases, [KCl] was
5.4 mM unless otherwise indicated. Tolb
and tolb., tolbutamide. Data were from
experiments on four to five separate cul-
tures involving the number of individual
cells shown on the bars (a and c) or 52 (b)
and 42 (d) separate cells. The time bars
indicate 60 s.
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AMPK-a2 activity was also strongly reversed by inhibition of
PI3K with LY294002 (Fig. 7).
DISCUSSION
Role of Insulin Secretion in the Regulation of the PPI Gene by
Glucose—This study demonstrates that, in the highly glucose-
responsive MIN6 b-cell line, stimulation of exocytosis by glu-
cose plays a key role in activating the L-PK gene as well as PPI
gene expression. It should be stressed that this study was
performed under conditions different from those of our recent
report (14), in which glucose was able to activate the PPI
promoter in MIN6 cells relatively weakly (;1.5-fold) and inde-
pendently of insulin secretion. Although not investigated in the
present study, it seems likely that changes in the distribution
(38, 40) or DNA-binding activity (60) of the homeodomain A3-
binding protein PDX-1 (pancreatic duodenum homeobox-1; for-
merly termed IPF-1, IDX-1, STF-1, and IUF-1) (61) are likely to
play an important role in this activation.
Comparison of the Role of Insulin Secretion in the Regulation
of PPI and L-PK Genes by Glucose—In this report, we demon-
strate that the L-PK gene, in common with the PPI gene, can be
regulated largely by glucose through the stimulation of insulin
secretion. Thus, we have used three approaches to distinguish
between the roles of 1) insulin secretion, 2) changes in [Ca21]i,
and 3) glucose metabolism in the regulation of transcription. It
should be emphasized that our measurements of [Ca21]i and
intracellular free [ATP] (Figs. 3, 4, and 6) were made only over
the short term (minutes) compared with the longer incubations
(hours) used in measurements of gene expression. These should
therefore only be taken as a guide to the changes in these
parameters during the full time course of measurements of
gene expression (6 h). Nevertheless, the former measurements
were considered important since several maneuvers that block
secretion (e.g. by preventing increases in [Ca21]i) can also par-
tially inhibit glucose metabolism and thus the generation of
potential intracellular signaling molecules (e.g. Glu-6-P or xy-
lulose 5-phosphate.3 For example, verapamil, which completely
suppressed the induction of PPI and L-PK promoter activities
by 30 mM glucose (Figs. 1 and 2), also suppresses increases in
[Ca21]i and intracellular [ATP].
3 On the other hand, diazoxide,
which blocked insulin secretion and the increase in [Ca21]i
(Fig. 3c), but not glucose metabolism (Fig. 3d), was also effi-
cient in blocking L-PK promoter induction (Fig. 3a). Finally,
clonidine, which blocks insulin secretion, but has no effect on
glucose metabolism and little effect on [Ca21]i,
3 was also a
FIG. 5. Effect of inhibiting PI3K function on L-PK promoter
activity. a, MIN6 cells were microinjected as described under “Exper-
imental Procedures” with plasmids pCMV-RL and pLPK-LucFF or
p(2150)LPK-LucFF (2150L-PK) (as indicated) before 6 h of culture at 3
or 30 mM glucose as indicated in the absence or presence of 50 mM
LY294002. *** and *, p , 0.001 and p , 0.05 for the effect of glucose,
respectively. b, same as a, but with co-microinjection of the plasmid
encoding Dp85 or the corresponding empty vector (pSRa; Control). ***
and 111, p , 0.001 for the effect of 30 mM glucose and LY294002,
respectively. c, same as a, but after co-injection of the expression plas-
mid encoding PTEN or the empty vector (pCMV5; Control) as indicated.
11, p , 0.01 for the effect of PTEN expression relative to the control
(30 mM glucose).
FIG. 6. Impact of insulin and glucose on glucokinase promoter
activity and glucose metabolism in single cells. a, cells were
microinjected with plasmids bGK4-Luc (0.1 mg/ml) and pRL-CMV (0.05
mg/ml) and incubated for 6 h at the indicated glucose concentrations or
at 3 mM glucose in the presence of 20 nM insulin (Ins). b–d, shown is the
response of cytoplasmic [ATP] in MIN6 cells to 30 mM glucose. b, cells
were transduced with adenoviral luciferase (AdCMVcLuc; see “Experi-
mental Procedures”) plus adenovirus expressing GK (closed circles;
GK1) or empty virus (open circles). 16 h after infection, the cells were
preincubated for 1 h in KRB buffer at 0 mM glucose before perifusion in
the presence of 5 mM luciferin for detection of luciferase light emission
(see “Experimental Procedures”) at the indicated glucose concentra-
tions. c, cells expressing AdCMVcLuc alone were incubated for 6 h in
culture medium containing 3 mM glucose and either 20 nM insulin
(closed circles) or no insulin (open circles), and the response of [ATP] to
a change in glucose from 3 to 30 mM glucose was measured as shown. d,
cells were incubated for 16 h in medium containing 3 mM glucose and
then subsequently perifused with KRB buffer supplemented with 3 mM
glucose alone (open circles) or 3 mM glucose and 20 nM insulin (closed
circles). After 5 min of pre-perifusion, the glucose concentration was
then changed to 30 mM as shown (620 nM insulin as appropriate). The
time bars represent 100 s.
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potent inhibitor of L-PK promoter induction (Fig. 3b). Together,
these data suggest that insulin secretion, but not an increase in
glucose metabolism or increases in [Ca21]i, is the chief trigger
for L-PK gene activation by glucose in the MIN6 b-cell model.
The induction of the PPI promoter by insulin reported here is
consistent with recent reports (9) and with the effects of a
range of nutrient secretagogues in HIT-T15 cells (15) and
MIN6 cells (60). Strikingly, higher concentrations of either KCl
or tolbutamide exerted no stimulatory effect on the apparent
transcriptional activity of either the PPI or L-PK gene or were
inhibitory (Fig. 4, a and c). We suspect that this may be due to
toxic effects of sustained high Ca21 levels in the b-cell type, i.e.
the positive effect of the released insulin may be counteracted
by the negative influence of high [Ca21]i. It should be noted
that the stimulatory effects of higher concentrations of KCl (50
mM) or tolbutamide (100 mM) on PPI mRNA levels, observed in
previous studies (9), involved cell stimulation for only 5 min
and extraction of RNA after 90 min. The absence of any effect
of higher concentrations (100 nM) of insulin on L-PK promoter
activity (Fig. 2C) in the present work may be related to in-
creases in [Ca21]i caused by added insulin itself (62)
3 and thus
to deleterious effects on cell function. These may become par-
ticularly pronounced over longer periods of culture and may
explain the absence of stimulation by sulfonylurea seen after
culture of islets for 48 h by de Vargas et al. (13). More difficult
to explain, however, is the absence of a negative effect of either
nifedipine or verapamil in these earlier studies and in those of
Goodison et al. (15) in HIT-T15 cells. Whether these agents
remain stable over very extended periods (.24 h) of culture is,
however, uncertain; metabolism of verapamil in vivo has been
described (63).
Role of PI3K in the Regulation of L-PK and PPI Genes—A
number of recent studies (9, 38, 60, 64) have implicated a role
for PI3K in the regulation of the PPI promoter. The involve-
ment of PI3K activity in the regulation of the L-PK promoter
was demonstrated in these studies through the effects of
LY294002 and dominant negative-acting p85. Interestingly,
the 39-inositol lipid kinase activity of the enzyme appeared to
be crucial since the effects of glucose were also reversed by
expression of the 39-phosphatase PTEN (Fig. 5c). Introduction
of PTEN also caused a paradoxical activation of L-PK promoter
activity in cells maintained at low glucose, although the mech-
anism involved in this induction remains obscure. These data
also suggest that the production of 39-phosphorylated lipids,
rather than the protein kinase activity of PI3K, is responsible
for both the activatory and inhibitory effects of the enzyme.
Whether this reflects different pools or species of inositol lipid
(e.g. phosphatidylinositol 3,4-bisphosphate versus PIP3) re-
mains to be elucidated.
Our study also demonstrates that stimulation of PI3K activ-
ity by elevated glucose concentrations, as recently reported in
INS-1 b-cells (65), is necessary for the induction of the L-PK
gene by insulin. Compatible with the idea that this involves a
para/autocrine effect of secreted insulin, Harvey et al. (66) have
recently demonstrated that added insulin increases PIP3 levels
in the rat CRI-G1 insulinoma cell line, presumably by the
activation of PI3K. Similarly, our own studies have demon-
strated that either 30 mM glucose or 20 nM insulin increases
both PIP3 levels and type I PI3K activity in MIN6 cells
2–3-fold.4
Role of AMPK—We recently demonstrated that inhibition of
AMPK is a critical event in the regulation of L-PK promoter
activity by glucose (52). Thus, activation of AMPK with 5-ami-
noimidazole-4-carboxamide ribonucleoside, which is converted
into the AMP analogue 5-aminoimidazole-4-carboxamide ribo-
nucleoside monophosphate (67), leads to the suppression of
L-PK gene expression in liver (30, 68) as well as in b-cell-
derived HIT-T15, INS-1 (69), and MIN6 (52) cells. Specific
inhibition of the a2 isoform of AMPK by antibody microinjec-
tion fully mimics the effect of high glucose concentrations on
L-PK promoter activity in MIN6 cells (52). Incubation of islets
with 5-amino-4-imidazolecarboxamide riboside leads to a weak
activation of insulin secretion at low glucose concentrations,
but then substantially inhibits further increases in insulin
release as the glucose concentration is elevated (69, 70). It is
therefore possible, but at present not proven, that inhibition of
AMPK activity, achieved by the microinjection of antibodies
into single cells, may lead to an activation of insulin secretion
at low glucose concentrations. The released insulin may then,
in turn, bind to insulin receptors and activate PPI and L-PK
gene transcription. Consistent with this view, the activation of
L-PK promoter activity resulting from the microinjection of
anti-AMPK-a2 antibodies was also sensitive to PI3K blockade
(Fig. 7). These observations suggest that AMPK lies either on a
signaling pathway upstream of PI3K or on a separate signaling
pathway that is responsible for repression of the L-PK gene in
low glucose.
This study supports the view that the L-PK promoter may be
regulated by insulin through both glucose metabolism-depend-
ent and -independent pathways. The relative importance of
these pathways may, however, depend on the cell type and
culture conditions. First, as demonstrated in this study on
MIN6 cells, insulin can act via a signaling pathway that in-
volves PI3K and presumably a subsequent protein kinase cas-
cade, perhaps involving phospholipid-dependent kinase-1 and
protein kinase B/Akt (71). Second, in liver and INS-1 b-cells,
changes in the intracellular concentration of a glucose metab-
olite such as Glu-6-P may also activate L-PK gene transcription
directly. Thus, 2-deoxyglucose increased the level of L-PK
mRNA in INS-1 cells (;1.5-fold increase at 10 mM 2-deoxyglu-
cose) (3), albeit more weakly than glucose (3-fold increase at 10
mM). The poorer efficacy of 2-deoxyglucose compared with glu-
cose in L-PK gene transcription may reflect its inability to
3 A.Varadi, unpublished data.
4 I. Rafiq, K. Venkateswarlu, P. Shepherd, and G. A. Rutter, unpub-
lished data.
FIG. 7. Effect of LY294002 on the stimulation of L-PK promoter
activity by anti-AMPK-a2 antibodies. Cells were microinjected with
plasmids pLPK-LucFF and pCMV-RL and with control IgG or anti-
AMPK-a2 antibodies (1.5 mg/ml) and incubated at the indicated glucose
concentrations in the presence or absence of 50 mM LY294002 (hatched
bars). *** and *, p , 0.001 and p ,0.05 for the effect of 30 mM glucose,
respectively; 111 and 1, p , 0.001 and p , 0.05 for the effect of
LY294002, respectively. Data in the first through fourth bars are trans-
posed from Fig. 5 for comparison.
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stimulate insulin secretion efficiently (72). Furthermore, inhi-
bition of PI3K activity and dephosphorylation of 39-phosphoi-
nositides both blocked the effects of glucose, implicating insulin
receptor activation as an early event in the signal transduction
pathway leading to transcriptional activation. Importantly,
these data also suggest that the PPI and L-PK genes are
regulated directly by insulin, and not indirectly as a result of
induction of GK and stimulation of glucose phosphorylation.
Thus, GK gene expression (Fig. 6a) and glucose metabolism
(Fig. 6, b and c) were unaltered by culture with insulin in this
model, consistent with the absence of changes in islet GK gene
expression in starved versus fed animals (32). It therefore
seems likely that the increase in L-PK promoter activity (this
work) and L-PK mRNA levels (73) may be due to the activation
of insulin secretion under these conditions (73).
Potential Signaling Pathways and Transcription Factors In-
volved in the Regulation of L-PK Gene Transcription by Glucose
and Insulin—An important question is to define the molecular
target of the two potential signaling mechanisms leading to the
induction of the L-PK gene. One intriguing possibility is that
both pathways converge on a single target molecule, which may
be phosphorylated by an insulin-activated protein kinase.
Changes in the intracellular levels of Glu-6-P/xylulose 5-phos-
phate could then interact with this pathway by influencing the
phosphorylation state of this target through changes in the
activity of a protein phosphatase (such protein phosphatase
2A) (30, 34).
What may be the target of the putative phosphorylation
event described above? Both SREBP-1c (74) and USF1/USF2
(26, 27) have been implicated in the regulation by glucose of the
L-PK promoter in liver, but their respective roles are at present
uncertain (75). Each of these factors binds to oligonucleotides
corresponding to the L-PK L4 box, with USF1/2 binding with
the greatest avidity (33). In islet b-cells, injection of blocking
antibodies demonstrated that USF2 function is essential for
L-PK induction by glucose (26). However, a dominant-negative
form of USF2 was found to be ineffective in inhibiting L-PK
gene induction in INS-1 cells (28) and liver cells (29). We have
found that suppression of SREBP-1c function in MIN6 cells
with a dominant-negative form of the protein (74) markedly
reduces glucose-activation of the promoter,5 suggesting that
this factor is required for the regulation of the gene in b-cells.
However, the L-PK promoter appears to be less dependent
upon SREBP-1c activity than other glucose-regulated genes in
b-cells6 and liver cells (74–76).
Conclusion—These studies demonstrate that both the PPI
and L-PK promoters can be regulated by insulin in MIN6
b-cells. In this model system, release of insulin and the activa-
tion of a PI3K-dependent signaling pathway may be the pre-
dominant mechanisms by which glucose activates glucose-sen-
sitive promoters (Fig. 8).
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